{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:38:02Z","timestamp":1790775482118,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD), previously referred to as non\u2010alcoholic fatty liver disease (NAFLD), has become the most prevalent chronic liver disease worldwide. Its increasing incidence is closely linked with rising rates of obesity, Type 2 diabetes mellitus (T2DM), and metabolic syndrome. MASLD includes a spectrum of liver pathologies such as fibrosis, cirrhosis, and metabolic dysfunction\u2013associated steatohepatitis (MASH). This review explores diagnostic advancements and therapeutic developments, focusing on Resmetirom, a selective thyroid hormone receptor\u2010beta (THR\u2010\u03b2) agonist, as a novel pharmacologic intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The review draws upon current literature, clinical guidelines, and data from pivotal randomized controlled trials to evaluate the diagnostic criteria, non\u2010invasive assessment tools, lifestyle recommendations, and emerging pharmacotherapy for MASLD and MASH, focusing on Resmetirom.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Resmetirom has demonstrated significant efficacy in reducing hepatic fat content and improving markers of liver fibrosis in patients with noncirrhotic MASH and fibrosis stages F2\u2013F3. Clinical trials showed improved liver histology, lipid profiles, and MASH resolution without fibrosis progression. Despite its promising profile, gastrointestinal side effects and gallstone\u2010related complications have been observed. Long\u2010term safety and outcomes related to cirrhosis or hepatocellular carcinoma prevention remain under investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MASLD is a significant public health concern driven by metabolic dysfunction. While lifestyle changes remain central to management, Resmetirom offers a promising pharmacological option for patients with moderate to advanced MASH. Further long\u2010term studies are needed to fully establish its safety, effectiveness, and role in preventing advanced liver disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.70920","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:19:13Z","timestamp":1750216753000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD)"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0840-9803","authenticated-orcid":false,"given":"Laiba","family":"Shakeel","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Dow University of Health Sciences Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1541-3037","authenticated-orcid":false,"given":"Ayesha","family":"Shaukat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Dow University of Health Sciences Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-1215","authenticated-orcid":false,"given":"Aymar","family":"Akilimali","sequence":"additional","affiliation":[{"name":"Department of Research Medical Research Circle (MedReC) Goma Democratic Republic of the Congo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/HEP.25762"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/HEP.30251"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/GUTJNL-2016-312238"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/DSI23-0010"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEP.2024.04.031"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00193-6"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEP.2024.01.014"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JHEP.2015.11.004"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/S40842-024-00187-4"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3748\/WJG.V30.I47.5070"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-99649-5.00019-4"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/JCM14041042"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1152\/AJPGI.00026.2023"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1590\/1806-9282.62.09.872"},{"key":"e_1_2_12_18_1","unstructured":"fda cder. Highlights of Prescribing Information."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/LIV.15930"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.METABOL.2024.155835"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/S41591-023-02603-1"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70242-8"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002195"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.70920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T04:07:13Z","timestamp":1765512433000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.70920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/hsr2.70920"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.70920","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2024-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70920"}}